Comparison of demographic variables by age group
| . | ≤10 y (n = 129) . | >10 y (n = 189) . | Total (N = 318) . | P value . |
|---|---|---|---|---|
| Age, y | ||||
| Mean (SD) | 5.0 (3.1) | 26.1 (17.2) | 17.5 (16.9) | <.001 |
| Median, range | 5.0 (0.0-10.0) | 18.0 (11.0-70.0) | 13.0 (0.0-70.0) | |
| AYA (aged >10-18 y) | 100 (52.9) | |||
| Sex | ||||
| Female | 57 (44.19) | 81 (42.86) | 138 (43.40) | .90 |
| Male | 72 (55.81) | 108 (57.14) | 180 (56.60) | |
| White, non-Hispanic | ||||
| No | 61 (47.29) | 65 (34.39) | 126 (39.62) | .03 |
| Yes | 68 (52.71) | 124 (65.61) | 192 (60.38) | |
| Race | ||||
| Native American, Native Hawaiian | 1 (0.78) | 2 (1.06) | 3 (0.94) | .23 |
| Asian | 5 (3.88) | 5 (2.65) | 10 (3.14) | |
| Black or African American | 17 (13.18) | 22 (11.64) | 39 (12.26) | |
| >1 Race/unknown/other | 23 (17.83) | 19 (10.05) | 42 (13.21) | |
| White | 83 (64.34) | 141 (74.60) | 224 (70.44) | |
| Ethnicity | ||||
| Hispanic | 23 (18.55) | 26 (13.90) | 49 (15.76) | .35 |
| Non-Hispanic | 101 (81.45) | 161 (86.10) | 262 (84.24) | |
| Malignant vs nonmalignant | ||||
| Malignant | 64 (49.61) | 142 (75.13) | 206 (64.78) | <.001 |
| Nonmalignant | 65 (50.39) | 47 (24.87) | 112 (35.22) | |
| Disease risk index∗ | ||||
| Low/intermediate | 33 (51.56) | 85 (59.86) | 118 (57.28) | .34 |
| High | 31 (48.44) | 57 (40.14) | 88 (42.72) | |
| Transplant donor | ||||
| Related | 56 (43.41) | 97 (51.32) | 153 (48.11) | .20 |
| Unrelated | 73 (56.59) | 92 (48.68) | 165 (51.89) | |
| Graft source | ||||
| Marrow† | 116 (89.92) | 113 (59.79) | 229 (72.01) | <.001 |
| PBSCs | 13 (10.08) | 76 (40.21) | 89 (27.99) | |
| HLA match | ||||
| ≥8/8 | 104 (80.62) | 169 (89.42) | 273 (85.85) | .06 |
| <7/8, noncord‡ | 5 (3.88) | 6 (3.17) | 11 (3.46) | |
| <7/8, cord | 20 (15.50) | 14 (7.41) | 34 (10.69) | |
| Conditioning regimen intensity | ||||
| Full | 98 (75.97) | 130 (68.78) | 228 (71.70) | .20 |
| Reduced | 31 (24.03) | 59 (31.22) | 90 (28.30) | |
| GVHD prophylaxis | ||||
| MTX and CNI | 70 (54.69) | 81 (44.51) | 151 (48.71) | <.001 |
| MMF and CNI | 32 (25.00) | 26 (14.29) | 58 (18.71) | |
| PTCY | 24 (18.75) | 24 (13.19) | 48 (15.48) | |
| Other prophylaxis§ | 2 (1.56) | 51 (28.02) | 53 (17.10) | |
| ATG/alemtuzumab | ||||
| Yes | 48 (37.21) | 45 (23.81) | 93 (29.25) | .014 |
| Previous aGVHD grade 2-4 | 35 (27.13) | 60 (31.75) | 95 (29.87) | .45 |
| cGVHD and maximum severity | ||||
| Yes | 28 (21.71) | 71 (37.57) | 99 (31.13) | .004 |
| Mild | 14 (10.85) | 20 (10.58) | 34 (10.69) | |
| Moderate/severe | 14 (10.85) | 51 (26.98) | 65 (20.44) | |
| Time from HCT to cGVHD, d | ||||
| Median (IQR) | 184.5 (113.25-262.25) | 176.5 (110.5-282.5) | 180 (111-280) |
| . | ≤10 y (n = 129) . | >10 y (n = 189) . | Total (N = 318) . | P value . |
|---|---|---|---|---|
| Age, y | ||||
| Mean (SD) | 5.0 (3.1) | 26.1 (17.2) | 17.5 (16.9) | <.001 |
| Median, range | 5.0 (0.0-10.0) | 18.0 (11.0-70.0) | 13.0 (0.0-70.0) | |
| AYA (aged >10-18 y) | 100 (52.9) | |||
| Sex | ||||
| Female | 57 (44.19) | 81 (42.86) | 138 (43.40) | .90 |
| Male | 72 (55.81) | 108 (57.14) | 180 (56.60) | |
| White, non-Hispanic | ||||
| No | 61 (47.29) | 65 (34.39) | 126 (39.62) | .03 |
| Yes | 68 (52.71) | 124 (65.61) | 192 (60.38) | |
| Race | ||||
| Native American, Native Hawaiian | 1 (0.78) | 2 (1.06) | 3 (0.94) | .23 |
| Asian | 5 (3.88) | 5 (2.65) | 10 (3.14) | |
| Black or African American | 17 (13.18) | 22 (11.64) | 39 (12.26) | |
| >1 Race/unknown/other | 23 (17.83) | 19 (10.05) | 42 (13.21) | |
| White | 83 (64.34) | 141 (74.60) | 224 (70.44) | |
| Ethnicity | ||||
| Hispanic | 23 (18.55) | 26 (13.90) | 49 (15.76) | .35 |
| Non-Hispanic | 101 (81.45) | 161 (86.10) | 262 (84.24) | |
| Malignant vs nonmalignant | ||||
| Malignant | 64 (49.61) | 142 (75.13) | 206 (64.78) | <.001 |
| Nonmalignant | 65 (50.39) | 47 (24.87) | 112 (35.22) | |
| Disease risk index∗ | ||||
| Low/intermediate | 33 (51.56) | 85 (59.86) | 118 (57.28) | .34 |
| High | 31 (48.44) | 57 (40.14) | 88 (42.72) | |
| Transplant donor | ||||
| Related | 56 (43.41) | 97 (51.32) | 153 (48.11) | .20 |
| Unrelated | 73 (56.59) | 92 (48.68) | 165 (51.89) | |
| Graft source | ||||
| Marrow† | 116 (89.92) | 113 (59.79) | 229 (72.01) | <.001 |
| PBSCs | 13 (10.08) | 76 (40.21) | 89 (27.99) | |
| HLA match | ||||
| ≥8/8 | 104 (80.62) | 169 (89.42) | 273 (85.85) | .06 |
| <7/8, noncord‡ | 5 (3.88) | 6 (3.17) | 11 (3.46) | |
| <7/8, cord | 20 (15.50) | 14 (7.41) | 34 (10.69) | |
| Conditioning regimen intensity | ||||
| Full | 98 (75.97) | 130 (68.78) | 228 (71.70) | .20 |
| Reduced | 31 (24.03) | 59 (31.22) | 90 (28.30) | |
| GVHD prophylaxis | ||||
| MTX and CNI | 70 (54.69) | 81 (44.51) | 151 (48.71) | <.001 |
| MMF and CNI | 32 (25.00) | 26 (14.29) | 58 (18.71) | |
| PTCY | 24 (18.75) | 24 (13.19) | 48 (15.48) | |
| Other prophylaxis§ | 2 (1.56) | 51 (28.02) | 53 (17.10) | |
| ATG/alemtuzumab | ||||
| Yes | 48 (37.21) | 45 (23.81) | 93 (29.25) | .014 |
| Previous aGVHD grade 2-4 | 35 (27.13) | 60 (31.75) | 95 (29.87) | .45 |
| cGVHD and maximum severity | ||||
| Yes | 28 (21.71) | 71 (37.57) | 99 (31.13) | .004 |
| Mild | 14 (10.85) | 20 (10.58) | 34 (10.69) | |
| Moderate/severe | 14 (10.85) | 51 (26.98) | 65 (20.44) | |
| Time from HCT to cGVHD, d | ||||
| Median (IQR) | 184.5 (113.25-262.25) | 176.5 (110.5-282.5) | 180 (111-280) |
Data are given as number (%), unless shown otherwise.
AYA, adolescent and young adult; CIBMTR, Center for International Blood and Marrow Transplant Research; CNI, calcineurin inhibitors; IQR, interquartile range; MMF, mycophenolate mofetil; MTX, methotrexate; PBSCs, peripheral blood stem cells; PTCY, post-HCT cyclophosphamide.
Disease risk index was calculated with the CIBMTR tool: https://www.cibmtr.org/ReferenceCenter/Statistical/Tools/Pages/DRI.aspx
Also included in this group: cord/double cord (n = 28 in aged ≤10 years, and n = 15 in aged >10 years).
Most of the HLA mismatches were due to the use of cord or double cord; for bone marrow and PBSC grafts there were 11 HLA mismatches: HCT with HLA <7/8 (n = 4), 6/8 (n = 1), 5/6 (n = 2), 4/6 (n = 1), and 3/6 (n = 3).
Among other prophylaxis, abatacept n = 2 (n = 1, ≤10 years; n = 1, >10 year), αβ T-cell depletion (n = 1, ≤10 years), CD34+ selection (n = 1, ≤10 years).